Antiretroviral therapy coverage for PMTCT in Tajikistan

Tajikistan: Antiretroviral therapy coverage for PMTCT was 92.0% in 2024. ◆ Volatile

Latest (2024)
92.0%
Change on year
down 3.2%
World rank
22nd
of 84 countries
All-time high
100.0%
in 2022
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Antiretroviral therapy coverage for PMTCT in Tajikistan, 2000–2024

0204060801002000201220242000: 0 % of pregnant women living with HIV2001: 0 % of pregnant women living with HIV2002: 0 % of pregnant women living with HIV2003: 0 % of pregnant women living with HIV2004: 0 % of pregnant women living with HIV2005: 0 % of pregnant women living with HIV2006: 1 % of pregnant women living with HIV2007: 3 % of pregnant women living with HIV2008: 8 % of pregnant women living with HIV2009: 9 % of pregnant women living with HIV2010: 15 % of pregnant women living with HIV2011: 21 % of pregnant women living with HIV2012: 29 % of pregnant women living with HIV2013: 36 % of pregnant women living with HIV2014: 53 % of pregnant women living with HIV2015: 55 % of pregnant women living with HIV2016: 60 % of pregnant women living with HIV2017: 57 % of pregnant women living with HIV2018: 80 % of pregnant women living with HIV2019: 66 % of pregnant women living with HIV2020: 78 % of pregnant women living with HIV2021: 79 % of pregnant women living with HIV2022: 100 % of pregnant women living with HIV2023: 95 % of pregnant women living with HIV2024: 92 % of pregnant women living with HIV

Source: UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Measured in % of pregnant women living with HIV.

Analysis

In 2024, antiretroviral therapy coverage for pmtct in Tajikistan stood at 92.0%.

Compared with earlier readings it is down 3.2% on the previous year and up 73.6% over ten years.

Over the whole period, antiretroviral therapy coverage for pmtct in Tajikistan peaked at 100.0% in 2022 and was at its lowest, 0.0%, in 2000.

Tajikistan ranks 22nd of 84 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Antiretroviral therapy coverage for PMTCT in Tajikistan, year by year

Annual values for Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV) in Tajikistan, 2000 to 2024.
Year % of pregnant women living with HIV Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 1.0%
2007 3.0% +200.0%
2008 8.0% +166.7%
2009 9.0% +12.5%
2010 15.0% +66.7%
2011 21.0% +40.0%
2012 29.0% +38.1%
2013 36.0% +24.1%
2014 53.0% +47.2%
2015 55.0% +3.8%
2016 60.0% +9.1%
2017 57.0% -5.0%
2018 80.0% +40.4%
2019 66.0% -17.5%
2020 78.0% +18.2%
2021 79.0% +1.3%
2022 100.0% +26.6%
2023 95.0% -5.0%
2024 92.0% -3.2%

Tajikistan compared with similar countries

  • Tajikistan's 92.0% is above the median for lower middle income countries, which is 83.5%, 1.1× the median. (32 countries reporting)
  • Tajikistan's 92.0% is above the median for Europe & Central Asia, which is 91.0%, 1.0× the median. (8 countries reporting)

Biggest year-on-year movements

Years where Antiretroviral therapy coverage for PMTCT in Tajikistan changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
2007 +200.0% 1.0% 3.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 2.1% 0.0% 9.0% 10
2010s 47.2% 15.0% 80.0% 10
2020s 88.8% 78.0% 100.0% 5

Countries ranked near Tajikistan

  1. 20 Sierra Leone 93.0% compare
  2. 20 Zimbabwe 93.0% compare
  3. 22 Canada 92.0% compare
  4. 22 Ethiopia 92.0% compare
  5. 25 Peru 91.0% compare

See the full ranking of 99 places →

More health data for Tajikistan

All data for Tajikistan →

Frequently asked questions

What is antiretroviral therapy coverage for pmtct in Tajikistan?
Antiretroviral therapy coverage for pmtct in Tajikistan was 92.0% in 2024, according to UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS).
What is the highest antiretroviral therapy coverage for pmtct recorded in Tajikistan?
The highest recorded value was 100.0% in 2022.
What is the lowest antiretroviral therapy coverage for pmtct recorded in Tajikistan?
The lowest recorded value was 0.0% in 2000.
How does Tajikistan rank for antiretroviral therapy coverage for pmtct?
Tajikistan ranks 22nd out of 84 countries with data for 2024.
Is antiretroviral therapy coverage for pmtct rising or falling in Tajikistan?
Over the last ten years it is up 73.6%. The long-run trend across the full record is volatile.
Where does this Tajikistan data come from?
The figures come from UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS), published as part of Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Antiretroviral therapy coverage for PMTCT in Tajikistan. Statizoid, drawing on UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS). Retrieved 18 September 2026, from https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/tajikistan/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://health.statizoid.com/stat/antiretroviral-therapy-coverage-for-pmtct-percent-of-pregnant-women-living-with-hiv/tajikistan/">Antiretroviral therapy coverage for PMTCT in Tajikistan</a> — Statizoid

About this data

Indicator
Antiretroviral therapy coverage for PMTCT (% of pregnant women living with HIV)
Unit
% of pregnant women living with HIV
Source
UNAIDS estimates, Joint United Nations Programme on HIV/AIDS (UNAIDS)
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
99 places, 2,393 data points, 2000–2024
Last refreshed

Percentage of pregnant women with HIV who receive antiretroviral medicine for prevention of mother-to-child transmission (PMTCT).